These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 10529776)

  • 1. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins.
    Rappuoli R; Pizza M; Douce G; Dougan G
    Immunol Today; 1999 Nov; 20(11):493-500. PubMed ID: 10529776
    [No Abstract]   [Full Text] [Related]  

  • 2. LTK63 and LTR72, two mucosal adjuvants ready for clinical trials.
    Pizza M; Giuliani MM; Fontana MR; Douce G; Dougan G; Rappuoli R
    Int J Med Microbiol; 2000 Oct; 290(4-5):455-61. PubMed ID: 11111926
    [No Abstract]   [Full Text] [Related]  

  • 3. An enzymatically active a domain is required for cholera-like enterotoxins to induce a long-lived blockade on the induction of oral tolerance: new method for screening mucosal adjuvants.
    Bagley KC; Abdelwahab SF; Tuskan RG; Lewis GK
    Infect Immun; 2003 Dec; 71(12):6850-6. PubMed ID: 14638772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of receptor binding in the immunogenicity, adjuvanticity and therapeutic properties of cholera toxin and Escherichia coli heat-labile enterotoxin.
    Nashar TO; Williams NA; Hirst TR
    Med Microbiol Immunol; 1998 Jun; 187(1):3-10. PubMed ID: 9749977
    [No Abstract]   [Full Text] [Related]  

  • 5. Cholera-like enterotoxins and Regulatory T cells.
    Basset C; Thiam F; Martino CD; Holton J; Clements JD; Kohli E
    Toxins (Basel); 2010 Jul; 2(7):1774-95. PubMed ID: 22069660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic.
    Williams NA; Hirst TR; Nashar TO
    Immunol Today; 1999 Feb; 20(2):95-101. PubMed ID: 10098329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin.
    de Haan L; Verweij W; Agsteribbe E; Wilschut J
    Immunol Cell Biol; 1998 Jun; 76(3):270-9. PubMed ID: 9682971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The gastrointestinal immune system: cholera toxin and E. coli heat-labile enterotoxin as immunomodulators].
    Kim J; Kiyono H
    Tanpakushitsu Kakusan Koso; 2001 Mar; 46(4 Suppl):547-55. PubMed ID: 11268659
    [No Abstract]   [Full Text] [Related]  

  • 9. Delineation and comparison of ganglioside-binding epitopes for the toxins of Vibrio cholerae, Escherichia coli, and Clostridium tetani: evidence for overlapping epitopes.
    Angström J; Teneberg S; Karlsson KA
    Proc Natl Acad Sci U S A; 1994 Dec; 91(25):11859-63. PubMed ID: 7527546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholera toxin, LT-I, LT-IIa and LT-IIb: the critical role of ganglioside binding in immunomodulation by type I and type II heat-labile enterotoxins.
    Connell TD
    Expert Rev Vaccines; 2007 Oct; 6(5):821-34. PubMed ID: 17931161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
    Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal vaccines based on the use of cholera toxin B subunit as immunogen and antigen carrier.
    Lebens M; Holmgren J
    Dev Biol Stand; 1994; 82():215-27. PubMed ID: 7958476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADP-ribosylating enterotoxins as vaccine adjuvants.
    Lycke N; Lebrero-Fernández C
    Curr Opin Pharmacol; 2018 Aug; 41():42-51. PubMed ID: 29702466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic detoxification of bacterial toxins.
    Pizza M; Fontana MR; Scarlato V; Rappuoli R
    Methods Mol Med; 2003; 87():133-52. PubMed ID: 12958454
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunity to heat-labile enterotoxins of porcine and human Escherichia coli strains achieved with synthetic cholera toxin peptides.
    Jacob CO; Arnon R; Finkelstein RA
    Infect Immun; 1986 May; 52(2):562-7. PubMed ID: 3009330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological cross-reactivity between a heat-labile enterotoxin(s) of Escherichia coli and subunits of Vibrio cholerae enterotoxin.
    Clements JD; Finkelstein RA
    Infect Immun; 1978 Sep; 21(3):1036-9. PubMed ID: 361573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural biology and structure-based inhibitor design of cholera toxin and heat-labile enterotoxin.
    Fan E; O'Neal CJ; Mitchell DD; Robien MA; Zhang Z; Pickens JC; Tan XJ; Korotkov K; Roach C; Krumm B; Verlinde CL; Merritt EA; Hol WG
    Int J Med Microbiol; 2004 Oct; 294(4):217-23. PubMed ID: 15532979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Priming immunization against cholera toxin and E. coli heat-labile toxin by a cholera toxin short peptide-beta-galactosidase hybrid synthesized in E. coli.
    Jacob CO; Leitner M; Zamir A; Salomon D; Arnon R
    EMBO J; 1985 Dec; 4(12):3339-43. PubMed ID: 3004953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulation using bacterial enterotoxins.
    Simmons CP; Ghaem-Magami M; Petrovska L; Lopes L; Chain BM; Williams NA; Dougan G
    Scand J Immunol; 2001 Mar; 53(3):218-26. PubMed ID: 11251877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholera toxin: a paradigm for multi-functional engagement of cellular mechanisms (Review).
    De Haan L; Hirst TR
    Mol Membr Biol; 2004; 21(2):77-92. PubMed ID: 15204437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.